Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 4Nivolumab 4Magnetic Resonance Spectroscopy 4Temozolomide 2Specimen Handling 2Rituximab 2Radiotherapy 2Radiosurgery 2Paclitaxel 2Neoadjuvant Therapy 2Gemcitabine 2Dexamethasone 2Cisplatin 2Carboplatin 2venetoclax 1theanine 1temsirolimus 1tafasitamab 1sugemalimab 1senicapoc 1sacituzumab govitecan 1ruxolitinib 1perampanel 1paricalcitol 1pamiparib 1olaparib 1lutetium Lu 177 dotatate 1irinotecan sucrosofate 1glofitamab 1gadobutrol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Cell Count × 30 days × Clear all
NCT06318871 2026-05-11

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Dana-Farber Cancer Institute

Phase EARLY_PHASE1 Active not recruiting
5 enrolled
Genitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡